Danone Expands Infant Milk Recall to Six European Countries Following Detection of Cereulide
On February 5, 2026, Danone announced the expansion of its infant milk recalls in France, Poland, Austria, Germany, Hungary, Romania, and Switzerland. This decision affects several hundred batches of products in response to new recommendations from the European Food Safety Authority (EFSA) concerning cereulide toxin.
The recall covers several hundred batches, including more than 120 in Austria and Germany, and 119 in France. The affected brands include Gallia and Blédilait. The list can be viewed here on the Signal Conso website.
Reason for the Recall
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
This recall follows the EFSA's update of its recommendations on the tolerated threshold of cereulide toxin in infant formulas. Cereulide is a toxin produced by certain bacteria, which can cause diarrhea and vomiting in infants.
Health Authorities' Recommendations
Health authorities advise parents not to use the affected products and to return them to the point of sale. They have also ruled out the risk of an infant milk shortage following these recalls.
SectorAgroalimentaire · Grande consommation›Produits alimentaires
Context
Period
Period: 2025
Key reported figures
Revenue: 27 283 millions d’euros
Revenue growth: 4,5 %
Net income: 1 825 millions d’euros
Free cash flow: 2 799 millions d’euros
Net debt: 8 059 millions d’euros
Dividend per share: 2,25 euros
Guidance from the release
En 2025, nous avons de nouveau enregistré une croissance de qualité sur l’ensemble de nos activités.
Publication des résultats annuels 2025 : progression du chiffre d’affaires en données comparables et amélioration de la marge opérationnelle courante, avec une forte performance en Chine et des gains en Europe.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
